Literature DB >> 7737649

Insulinlike growth factor-II/mannose 6-phosphate receptor is expressed on CCl4-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-beta in cocultures with sinusoidal endothelial cells.

P J de Bleser1, P Jannes, S C van Buul-Offers, C M Hoogerbrugge, C F van Schravendijk, T Niki, V Rogiers, J L van den Brande, E Wisse, A Geerts.   

Abstract

Transforming growth factor beta (TGF-beta), a potent fibrogenic cytokine, is secreted in latent form. We examined which cell type in both normal and carbon tetrachloride (CCl4)-induced fibrotic rat liver bears surface type II IGF/mannose 6-phosphate (IGF-II/M6P) receptor, known to facilitate activation of TGF-beta. In addition, the role of the IGF-II/M6P receptor in activation of latent TGF-beta was investigated in a coculture system with sinusoidal endothelial cells. Northern hybridization analysis for IGF-II/M6P receptor messenger RNA (mRNA) was performed on total RNA of different isolated and purified liver cell types. In normal liver, cells expressed little IGF-II/M6P receptor mRNA. In fibrotic liver, we found significant expression only in fat-storing cells. The presence of IGF-II/M6P receptors was established by [125I]IGF-II binding assays on freshly isolated fat-storing cells from normal and CCl4-exposed rat livers. We found specific binding of [125I]IGF-II only on CCl4 exposed fat-storing cells. As determined by polyacrylamide gel electrophoresis after affinity labeling, the specific binding involved 220 kD type II IGF receptors. Scatchard analysis revealed the presence of 3,043 +/- 1,378 IGF-II/M6P high-affinity receptors/fat-storing cell, with a Kd of 387 = 165 pmol/L. With a mink lung epithelial cell (Mv1Lu) proliferation inhibition assay, inhibition of proliferation (a measure of active TGF-beta function) was determined using conditioned media of activated fat-storing cells, cocultures of fat-storing cells, and endothelial cells and pure endothelial cell cultures.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7737649     DOI: 10.1002/hep.1840210529

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

1.  Platelet-derived growth factor is a principal inductive factormodulating mannose 6-phosphate/insulin-like growth factor-II receptorgene expression via a distal E-box in activated hepatic stellate cells.

Authors:  J A Weiner; A Chen; B H Davis
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

Review 2.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

Review 3.  Genomic imprinting and cancer.

Authors:  J A Joyce; P N Schofield
Journal:  Mol Pathol       Date:  1998-08

Review 4.  Molecular mechanisms of hepatic fibrosis and principles of therapy.

Authors:  S L Friedman
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

5.  Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis.

Authors:  T Yamada; A T De Souza; S Finkelstein; R L Jirtle
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

Review 6.  Therapeutic targeting of liver inflammation and fibrosis by nanomedicine.

Authors:  Matthias Bartneck; Klaudia Theresa Warzecha; Frank Tacke
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

7.  Expression of the Na+/Ca2+ exchanger emerges in hepatic stellate cells after activation in association with liver fibrosis.

Authors:  T Nakamura; S Arii; K Monden; M Furutani; Y Takeda; M Imamura; M Tominaga; Y Okada
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

8.  A sequential, multiple-treatment, targeted approach to reduce wound healing and failure of glaucoma filtration surgery in a rabbit model (an American Ophthalmological Society thesis).

Authors:  Mark Brian Sherwood
Journal:  Trans Am Ophthalmol Soc       Date:  2006

Review 9.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

Review 10.  Nanotechnology applications for the therapy of liver fibrosis.

Authors:  Lydia Giannitrapani; Maurizio Soresi; Maria Luisa Bondì; Giuseppe Montalto; Melchiorre Cervello
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.